Anxiety

Overview

Category: Non-motor symptom (Neuropsychiatric)

Prevalence: Up to 40%

Detailed Information

Anxiety in PD can be both a direct effect of neurochemical changes and a psychological response to living with a chronic progressive condition. It frequently co-occurs with depression (more than 50% of anxious PD patients are also depressed) and can worsen during off-medication periods. Off-period anxiety is particularly common and responds to optimizing dopaminergic therapy. Panic-like episodes during wearing-off can be misdiagnosed as a primary panic disorder.

Anxiety manifests in PD-specific ways: fear of falling (common even before falls occur), social anxiety related to visible symptoms (tremor, dyskinesia, drooling), medication-related anxiety (worry about wearing off, running out of medications), and disease-progression anxiety. Internal tremor -- a subjective sensation of vibrating or shaking inside the body without visible tremor -- may accompany anxiety and is distressing to patients who struggle to describe the sensation.

Pathophysiology: Why This Happens

Anxiety in PD involves degeneration of multiple neurotransmitter systems. The locus coeruleus (norepinephrine), raphe nuclei (serotonin), and ventral tegmental area (dopamine) all show alpha-synuclein pathology and neuronal loss. The amygdala, a central structure in fear and anxiety processing, shows dopaminergic denervation in PD and altered connectivity with prefrontal regulatory regions.

The relationship between dopaminergic medication status and anxiety levels in many PD patients points to a direct role for dopamine in mood regulation. During off-periods, reduced dopamine in the mesolimbic reward pathway may trigger acute anxiety and panic. This pharmacokinetic coupling of motor and mood fluctuations -- termed non-motor fluctuations -- is increasingly recognized as a core feature of advancing PD.

Chronic stress and anxiety also have reciprocal effects on PD pathophysiology: elevated cortisol from chronic anxiety may accelerate neurodegeneration, and anxiety-related avoidance of exercise and social engagement removes protective factors.

Prevalence and Demographics

Anxiety disorders affect approximately 31-40% of PD patients, with some studies reporting rates as high as 60%. The most common presentations are generalized anxiety disorder (14-25%), social phobia (13-17%), and panic disorder (7-30%). Anxiety is significantly more prevalent in PD than in age-matched controls, other chronic diseases, and even other neurological conditions with similar disability levels.

Risk factors include female sex, younger age at PD onset, motor fluctuations, history of anxiety or mood disorders before PD, and the presence of depression or cognitive impairment. Anxiety often predates the PD motor diagnosis, similar to depression, suggesting a neurobiological basis. Off-period anxiety is particularly common in patients with motor fluctuations.

Differential Diagnosis

Several other conditions can cause similar symptoms. A thorough medical evaluation is essential to distinguish Parkinson's-related anxiety from other causes:

Medication-related anxiety should be distinguished from PD-related anxiety. Dopamine agonist withdrawal can cause severe anxiety and panic. Caffeine, sympathomimetic medications, and thyroid hormone excess can cause or worsen anxiety symptoms. Akathisia -- a medication-related inner restlessness that drives the urge to move -- can mimic anxiety and occurs with both dopaminergic and antipsychotic medications.

Cardiac arrhythmias, hypoglycemia, hyperthyroidism, and pheochromocytoma can produce anxiety-like symptoms and should be excluded when appropriate. Off-period dystonia with pain can trigger reactive anxiety that may be misattributed to a primary anxiety disorder. In patients with cognitive impairment, anxiety may reflect a disorientation response to unfamiliar settings or confusion rather than a primary mood disorder.

How This Symptom Changes by Stage

Anxiety may be present before motor diagnosis as part of the prodromal PD syndrome. In newly diagnosed patients, anxiety about the diagnosis itself -- its implications for career, family, independence, and mortality -- is common and appropriate. Clinical anxiety should be distinguished from normal concern.

In stages 2-3, medication-related anxiety fluctuations typically emerge. Patients begin to experience predictable periods of increased anxiety corresponding to wearing off of dopaminergic medication. Social anxiety may increase as visible symptoms (tremor, dyskinesia) become more apparent.

In stages 4-5, anxiety may relate increasingly to fears of falling, medication failure, and dependency. Generalized anxiety about the future -- loss of independence, caregiving burden, cognitive decline -- is common. Anxiety in advanced PD can be difficult to disentangle from concurrent depression, apathy, and cognitive impairment.

Stage-by-Stage Quick Reference

A summary of how anxiety typically presents at each Hoehn & Yahr stage:

Stage 1

May be present early

Stage 2

Can fluctuate with meds

Stage 3

Often significant

Stage 4

May be severe

Stage 5

Pervasive

Management Strategies

Optimizing dopaminergic therapy to reduce off-period fluctuations is the first-line approach for anxiety that is linked to wearing-off phenomena. Reducing off-time through COMT inhibitors, extended-release formulations, or infusion therapies often substantially improves medication-related anxiety.

SSRIs and SNRIs are the most commonly used pharmacological treatments for persistent anxiety in PD. Buspirone may be considered for generalized anxiety without the sedation or cognitive effects of benzodiazepines. Benzodiazepines should generally be avoided or used only short-term in PD due to risks of falls, sedation, cognitive impairment, and dependence -- particularly important in an elderly, balance-impaired population.

Cognitive behavioral therapy (CBT) adapted for PD has demonstrated efficacy for anxiety in randomized trials. Mindfulness-based stress reduction (MBSR) and acceptance and commitment therapy (ACT) have emerging evidence. Regular exercise is anxiolytic, and the social engagement of group exercise programs provides additional benefit.

Patient education about the neurobiological basis of anxiety in PD -- understanding that anxiety is a symptom of the disease, not a character weakness -- can itself be therapeutic. Support groups provide validation and shared coping strategies.

Practical Tips

• Regular exercise and mindfulness meditation
• Cognitive behavioral therapy
• Join a support group
• Track anxiety patterns relative to medication times
• Discuss treatment options with your doctor

When to See a Doctor

If anxiety interferes with daily activities, social interactions, or medication off-periods.

The Bigger Picture

Anxiety in PD is often overshadowed by depression in clinical attention, but it may be equally or more prevalent and equally damaging to quality of life. The wearing-off related pattern of anxiety in PD is particularly important to recognize because it is treatable by optimizing dopaminergic therapy -- a motor adjustment that simultaneously addresses a non-motor symptom.

Patients should be encouraged to track their anxiety patterns in relation to medication timing, using a symptom diary that records both motor and mood states throughout the day. This information enables neurologists to identify off-period anxiety and adjust medication timing accordingly, often producing dramatic improvement without needing to add a separate anxiolytic medication.